Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Head and Neck Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 46 articles: HTML format

Single Articles

September 2025
1. LU Z, Du W, Jiao X, Wang Y, et al
   Reply to: "NOTCH1: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma".
   J Clin Oncol. 2025 Sep 11:JCO2501535. doi: 10.1200/JCO-25-01535.
   PubMed    
   
   
   
2. LU Z, Yan K, Sheng Y, Rukonge PA, et al
   Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma.
   J Clin Oncol. 2025 Sep 11:JCO2501053. doi: 10.1200/JCO-25-01053.
   PubMed    
   
   
   
3. BOURHIS J, Licitra LF, Burtness B, Psyrri A, et al
   Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.
   J Clin Oncol. 2025 Sep 3:JCO2500272. doi: 10.1200/JCO-25-00272.
   PubMed     Abstract available
   
   
   
4. DOUGAN M, Dougan SK
   Second Mitochondrial Activator of Caspases Mimetics Accelerate Progression of Locally Advanced Head and Neck Cancer.
   J Clin Oncol. 2025 Sep 3:JCO2501024. doi: 10.1200/JCO-25-01024.
   PubMed    
   
   
   August 2025
5. BURTNESS B, Flamand Y, Quon H, Weinstein GS, et al
   Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer.
   J Clin Oncol. 2025;43:2559-2565.
   PubMed     Abstract available
   
   
   
6. SHITARA K, Lorenzen S, Li J, Bai Y, et al
   Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.
   J Clin Oncol. 2025;43:2502-2514.
   PubMed     Abstract available
   
   
   July 2025
7. VAN DEN BOSCH S, Hannink G, Kaanders JHAM
   Reply to: Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT.
   J Clin Oncol. 2025 Jul 22:JCO2501390. doi: 10.1200/JCO-25-01390.
   PubMed    
   
   
   
8. KIYOTA N, Mizusawa J, Zenda S, Yokota T, et al
   Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT.
   J Clin Oncol. 2025 Jul 22:JCO2500928. doi: 10.1200/JCO-25-00928.
   PubMed    
   
   
   
9. KAWAKAMI H, Kadowaki S, Makiyama A, Tsuda M, et al
   Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
   J Clin Oncol. 2025;43:2184-2195.
   PubMed     Abstract available
   
   
   May 2025
10. ZANDBERG DP, Vujanovic L, Clump DA, Isett BP, et al
    Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer.
    J Clin Oncol. 2025 May 27:JCO2401580. doi: 10.1200/JCO-24-01580.
    PubMed     Abstract available
    
    
    April 2025
11. VAN DEN BOSCH S, Doornaert PAH, Hoebers FJP, Kreike B, et al
    Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial.
    J Clin Oncol. 2025 Apr 15:JCO2402194. doi: 10.1200/JCO-24-02194.
    PubMed     Abstract available
    
    
    
12. HOLSINGER FC, Ismaila N, Adkins DR, Barber BR, et al
    Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline.
    J Clin Oncol. 2025;43:1369-1392.
    PubMed     Abstract available
    
    
    
13. LU Z, Du W, Jiao X, Wang Y, et al
    NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.
    J Clin Oncol. 2025 Apr 3:JCO2401818. doi: 10.1200/JCO-24-01818.
    PubMed     Abstract available
    
    
    February 2025
14. YAYLALI M, Halac B, Yalcin B
    Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.
    J Clin Oncol. 2025 Feb 19:JCO2402689. doi: 10.1200/JCO-24-02689.
    PubMed    
    
    
    
15. SWIECICKI PL, Yilmaz E, Rosenberg AJ, Fujisawa T, et al
    Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.
    J Clin Oncol. 2025 Feb 19:JCO2500028. doi: 10.1200/JCO-25-00028.
    PubMed    
    
    
    January 2025
16. MACHTAY M, Torres-Saavedra PA, Thorstad W, Nguyen-Tan PF, et al
    Postoperative Radiotherapy +/- Cetuximab for Intermediate-Risk Head and Neck Cancer.
    J Clin Oncol. 2025 Jan 22:JCO2401829. doi: 10.1200/JCO-24-01829.
    PubMed     Abstract available
    
    
    
17. KLEMPNER SJ, Sonbol MB, Wainberg ZA, Uronis HE, et al
    DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.
    J Clin Oncol. 2025;43:339-349.
    PubMed     Abstract available
    
    
    December 2024
18. NICHOLS AC, Theurer J, Prisman E, Read N, et al
    Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial.
    J Clin Oncol. 2024;42:4023-4028.
    PubMed     Abstract available
    
    
    October 2024
19. SWIECICKI PL, Yilmaz E, Rosenberg AJ, Fujisawa T, et al
    Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.
    J Clin Oncol. 2024 Oct 31:JCO2400646. doi: 10.1200/JCO.24.00646.
    PubMed     Abstract available
    
    
    
20. TOPKAN E, Somay E, Bascil S, Pehlivan B, et al
    Underrated But Significant Risk Factors of Osteoradionecrosis of the Jaw in Patients With Head and Neck Cancer.
    J Clin Oncol. 2024 Oct 3:JCO2401020. doi: 10.1200/JCO.24.01020.
    PubMed    
    
    
    
21. CHEN WJ, Yu X, Lu YQ, Pfeiffer RM, et al
    Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial.
    J Clin Oncol. 2024 Oct 1:JCO2301296. doi: 10.1200/JCO.23.01296.
    PubMed     Abstract available
    
    
    September 2024
22. WIRTH LJ, Brose MS, Subbiah V, Worden F, et al
    Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
    J Clin Oncol. 2024;42:3187-3195.
    PubMed     Abstract available
    
    
    August 2024
23. GARDEN AS
    Selecting Patients With Oropharyngeal Cancer for Lower Dose Radiation.
    J Clin Oncol. 2024;42:2835-2836.
    PubMed    
    
    
    July 2024
24. DZIENIS M, Cundom J, Fuentes CS, Spreafico A, et al
    Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.
    J Clin Oncol. 2024 Jul 22:JCO2302625. doi: 10.1200/JCO.23.02625.
    PubMed     Abstract available
    
    
    
25. XIA C, Li H, Chen W
    Reduction in Esophageal Cancer Incidence and Mortality by Screening Endoscopy.
    J Clin Oncol. 2024 Jul 10:JCO2400557. doi: 10.1200/JCO.24.00557.
    PubMed    
    
    
    June 2024
26. HEGEWISCH-BECKER S, Mendez G, Chao J, Nemecek R, et al
    First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
    J Clin Oncol. 2024;42:2080-2093.
    PubMed     Abstract available
    
    
    
27. HUANG CL, Zhang N, Jiang W, Xie FY, et al
    Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial.
    J Clin Oncol. 2024;42:2021-2025.
    PubMed     Abstract available
    
    
    
28. JANJIGIAN YY, Ajani JA, Moehler M, Shen L, et al
    First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
    J Clin Oncol. 2024;42:2012-2020.
    PubMed     Abstract available
    
    
    May 2024
29. GILLENWATER AM, Vigneswaran N, Sikora AG
    Assessing the Role of Inflammation in Oral Tongue Carcinogenesis.
    J Clin Oncol. 2024;42:1729-1730.
    PubMed    
    
    
    
30. TIAN Q, Jiang L, Dai D, Liu L, et al
    Impact of Postoperative Radiotherapy on the Prognosis of Early-Stage (pT1-2N0M0) Oral Tongue Squamous Cell Carcinoma.
    J Clin Oncol. 2024;42:1754-1765.
    PubMed     Abstract available
    
    
    
31. TOTA JE, Engels EA, Lingen MW, Agrawal N, et al
    Inflammatory Tongue Conditions and Risk of Oral Tongue Cancer Among the US Elderly Individuals.
    J Clin Oncol. 2024;42:1745-1753.
    PubMed     Abstract available
    
    
    
32. JIA R, Shan T, Zheng A, Zhang Y, et al
    Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.
    J Clin Oncol. 2024 May 6:JCO2302009. doi: 10.1200/JCO.23.02009.
    PubMed     Abstract available
    
    
    
33. WATSON E EE, Hueniken K, Lee J, Huang SH, et al
    Development and Standardization of an Osteoradionecrosis Classification System in Head and Neck Cancer: Implementation of a Risk-Based Model.
    J Clin Oncol. 2024 May 1:JCO2301951. doi: 10.1200/JCO.23.01951.
    PubMed     Abstract available
    
    
    
34. PETERSON DE, Koyfman SA, Yarom N, Lynggaard CD, et al
    Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy: ISOO-MASCC-ASCO Guideline.
    J Clin Oncol. 2024 May 1:JCO2302750. doi: 10.1200/JCO.23.02750.
    PubMed     Abstract available
    
    
    April 2024
35. WARDILL HR, Bossi P, Sonis ST
    Understanding Protective Mechanisms of an Oral Probiotic in Reducing Radiation-Induced Oral Mucositis.
    J Clin Oncol. 2024;42:1436-1438.
    PubMed    
    
    
    
36. PENG X, Li Z, Pei Y, Zheng S, et al
    Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial.
    J Clin Oncol. 2024;42:1426-1435.
    PubMed     Abstract available
    
    
    March 2024
37. LEE NY, Sherman EJ, Schoder H, Wray R, et al
    Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma.
    J Clin Oncol. 2024;42:940-950.
    PubMed     Abstract available
    
    
    
38. LIU M, Yang W, Guo C, Liu Z, et al
    Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial.
    J Clin Oncol. 2024 Mar 8:JCO2301284. doi: 10.1200/JCO.23.01284.
    PubMed     Abstract available
    
    
    February 2024
39. ZHU M, Yoon HH
    Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
    J Clin Oncol. 2024;42:373-377.
    PubMed    
    
    
    January 2024
40. SUN R, Liu J, Wei LJ
    Assessing Predictability of Pathologic Lymph Node Regression for Recurrence and Survival in Esophageal Adenocarcinoma.
    J Clin Oncol. 2024;42:366.
    PubMed    
    
    
    December 2023
41. 
    Erratum: Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
    J Clin Oncol. 2023 Dec 19:JCO2302629. doi: 10.1200/JCO.23.02629.
    PubMed    
    
    
    November 2023
42. LORENZEN S, Gotze TO, Thuss-Patience P, Biebl M, et al
    Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300975. doi: 10.1200/JCO.23.00975.
    PubMed     Abstract available
    
    
    October 2023
43. MOORE JL, Green M, Santaolalla A, Deere H, et al
    Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom.
    J Clin Oncol. 2023;41:4522-4534.
    PubMed     Abstract available
    
    
    
44. FARON M, Cheugoua-Zanetsie M, Tierney J, Thirion P, et al
    Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma.
    J Clin Oncol. 2023;41:4535-4547.
    PubMed     Abstract available
    
    
    September 2023
45. KIM CG, Jung M, Kim HS, Lee CK, et al
    Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
    J Clin Oncol. 2023;41:4394-4405.
    PubMed     Abstract available
    
    
    
46. KEAM B, Hong MH, Shin SH, Heo SG, et al
    Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
    J Clin Oncol. 2023 Sep 12:JCO2202786. doi: 10.1200/JCO.22.02786.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.